ESID
  • Users Online: 65
  • Print this page
  • Email this page
CASE REPORT
Year : 2018  |  Volume : 1  |  Issue : 1  |  Page : 46-48

Inflammatory colitis after treatment of melanoma with talimogene laherparepvec (T-VEC)


1 Department of Medicine (Dermatology) and Seattle Cancer Care Alliance, University of Washington, Seattle, WA, USA
2 Department of Pathology and Seattle Cancer Care Alliance, University of Washington, Seattle, WA, USA
3 Department of Medicine (Gastroenterology), University of Washington, Seattle, WA, USA
4 Department of Medicine (Oncology) and Seattle Cancer Care Alliance, University of Washington, Seattle, WA, USA

Correspondence Address:
Dr. Jennifer Gardner
16472 SE 46th Ct., Bellevue, WA 98006
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/JIPO.JIPO_3_18

Get Permissions

Talimogene laherparepvec (T-VEC) is an intralesional oncolytic viral therapy for the treatment of recurrent, unresectable cutaneous, subcutaneous, and nodal melanoma. It is thought to work through direct tumor oncolysis and by eliciting a tumor-specific systemic immune response. Immune-related adverse events have been reported only rarely with this therapy. We report a case of culture-negative, biopsy-proven colitis following pathologic complete response of recurrent, and intransit cutaneous melanoma to T-VEC. To the best of our knowledge, this is the first report of immune-related colitis following T-VEC.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed706    
    Printed54    
    Emailed1    
    PDF Downloaded55    
    Comments [Add]    

Recommend this journal